Pfizer Corporation

Jamison Bryce Tuttle

Patrick Robert Verhoest

Dafydd Rhys Owen

Matthew Forrest Sammons

Robert Steven Kania

Thomas Allen Chappie

Bethany Lyn Kormos

Matthew Richard Reese

Christopher John Helal

Martin Youngjin Pettersson

Simone Sciabola

Qingyi Yang

Travis T Wager

Amy Beth Dounay

Jaclyn Louise Henderson

Sajiv Krishnan Nair

Joseph Michael Young

Ru Zhou

Nandini Chaturbhai Patel

Xiaojing Yang

Mehran Jalaie

Michele Ann McTigue

Mingying He

Dahui Zhou

Joseph Walter Tucker

Liuqing Wei

Rebecca Anne Gallego

Matthew L Del Bel

Anne-Marie Dechert Schmitt

Matthew Merrill Hayward

Neelu Kaila

Tarek A Samad

Robert Louis Hoffman

Karen Jean Coffman

Ted William Johnson

Michael L Vazquez

Mihir D Parikh

Omar Khaled Ahmad

Samir Kulkarni

Suman Luthra

Klimentina Dimitrova Pencheva

Anil Mahadeo Rane

Sujin Cho-Schultz

Michelle Marie Claffey

Suobao Rong

Jonathan Richard Lillis

Martyn David Ticehurst

James M Duerr

Emma Louise Hawking

Rohit Jaini

Padmavani Bezawada

Andrew John Thiel

Bradley Paul Sullivan

Matthew Nathan O'Brien Laramy

Joyann Barber

Xinmin Gan

Michele Ann Mctigue

The invention relates to compounds of formula I wherein Rand Rare as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-COV-2 with the compound.

Compounds and method of treating COVID-19

The invention relates to compounds of formula I wherein R, Rand - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

Compounds and methods for the treatment of COVID-19

This invention relates to compounds of general Formula I

Azalactam compounds as HPK1 inhibitors

The invention relates to compounds of Formula I&#x2033; wherein R, R, R, R, p, q and q' are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

Nitrile-containing antiviral compounds

The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R, R, R, R, R, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression. 

6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands

This invention relates to compounds of general Formula (I) 

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.

Pyrrolo[2,3-d]pyrimidine derivatives

The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R, R, R, and Rare as defined herein and to the use of the compounds as PDE10 inhibitors. 

Triazine derivatives

The present invention relates to compounds 3-amino-1-hydroxy-2-oxo-1,2,3, 4-tetrahydroquinoline-7-carbonitrile, 3-amino-1-hydroxy-7-(2-methoxyethoxy)-3,4-dihydroquinolin-2(1H)-one, and 3-amino-1-hydroxy-7-[(1S)-2-methoxy-1-methylethoxy]-3,4-dihydroquinolin-2(1H)-one, including racemic mixtures and resolved enantiomers thereof, to pharmaceutically acceptable salts thereof, and to the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

KAT II inhibitors

Compounds of Formula X: wherein A, X, Y, Z, R, R, and Rare as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.

Bicyclic and tricyclic compounds as KAT II inhibitors

Growing community of inventors

Marblehead, MA, United States of America

Jamison Bryce Tuttle